UNMET NEED IN CONTROLLING INVASIVE PNEUMOCOCCAL DISEASE (IPD) AMONG CANADIAN OLDER ADULTS IN THE CONTEXT OF THE CURRENT AND POTENTIAL FUTURE PNEUMOCOCCAL VACCINATION PROGRAMS (ID 824)
- Stephane Dion, Canada
- Stephane Dion, Canada
- Rajeev Nepal, Canada
- Maria Major, Canada
- Ana Gabriela Grajales, Canada
- Jose A. Suaya, United States of America
- Bradford D. Gessner, United States of America
- Alejandro Cane, Argentina
- Jelena Vojicic, Canada
Abstract
Background
In Canadian adults aged ≥65, routine pneumococcal-polysaccharide-vaccine (PPV23) use has been recommended for several decades, and 13-valent pneumococcal conjugate vaccine (PCV13) on an individual basis - since 2016. When PCV13 is administered, sequential PPV23 is recommended to broaden serotype coverage.
We aimed to assess the proportion of PCV13-, PPV23/non13-, PCV15-, and PCV20-type IPD among Canadian older adults.
Methods
Proportions of IPD due to PCV13, PPV23/non13, PCV15 and PCV20 serotypes were calculated from case counts reported, by serotype and age group, from the National Microbiology Laboratory between 2010 and 2017.
Results
Among all IPD, the contribution of PCV13-type declined from 50% (487/967) to 23% (287/1,238). PPV23/non13-type IPD increased from 25% (240/967) to 39% (487/1,238). In 2017, IPD proportions due to PCV15- and PCV20-types were 36% (447/1,238) and 52% (646/1,238) (Figure 1).
Conclusions
Despite routine PPV23 program, increasing trend in cases and proportions of PPV23/non13-type IPD was noted during the observation period. Initial decline in PCV13-type IPD, likely an indirect effect of pediatric program, leveled off in recent years supporting the need for broad PCV13 use in older adults. PCV20, which shares 19 serotypes with PPV23, could address limitations of the PPV23 program in the ability to control vaccine-type IPD.